請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16761
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賴美淑 | |
dc.contributor.author | Hsu-Wen Chou | en |
dc.contributor.author | 周煦文 | zh_TW |
dc.date.accessioned | 2021-06-07T23:45:27Z | - |
dc.date.copyright | 2014-10-20 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-06-30 | |
dc.identifier.citation | 1. WHO. Pharmacovigilance: Ensuring the Safe Use of Medicines 2004.
2. Freemantle N, Marston L, Walters K, Wood J, Reynolds MR, Petersen I. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ 2013;347:f6409. 3. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003;158(3):280-7. 4. Council for International Organizations of Medical S. Guidelines for preparing core clinical-safety information on drugs : report of CIOMS Working Group III. Geneva, Switzerland: CIOMS, 1995. 5. ROSENBAUM PR, RUBIN DB. The central role of the propensity score in observational studies for causal effects. Biome 1983;70(1):41-55. 6. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006;98(3):253-9. 7. Sturmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 2005;161(9):891-8. 8. Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006;59(5):437-47. 9. Imbens G. The role of the propensity score in estimating dose-response functions. Biome 2000;87(3):706-10. 10. Luellen JK, Shadish WR, Clark MH. Propensity scores: an introduction and experimental test. Evaluation review 2005;29(6):530-58. 11. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127(8 Pt 2):757-63. 12. Spreeuwenberg MD, Bartak A, Croon MA, et al. The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health. Med Care 2010;48(2):166-74. 13. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999;150(4):327-33. 14. Cadarette SM, Gagne JJ, Solomon DH, Katz JN, Sturmer T. Confounder summary scores when comparing the effects of multiple drug exposures. Pharmacoepidemiol Drug Saf 2010;19(1):2-9. 15. Rassen JA, Solomon DH, Glynn RJ, Schneeweiss S. Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic “matrix design”. Pharmacoepidemiol Drug Saf 2011;20(7):675-83. 16. Rassen JA, Solomon DH, Curtis JR, Herrinton L, Schneeweiss S. Privacy-Maintaining Propensity Score-Based Pooling of Multiple Databases Applied to a Study of Biologics. Med Care 2010;48(6):S83-S9. 17. Rassen JA, Shelat AA, Franklin JM, Glynn RJ, Solomon DH, Schneeweiss S. Matching by Propensity Score in Cohort Studies with Three Treatment Groups. Epidemiology 2013;24(3):401-9. 18. Wang J, Donnan PT, Steinke D, MacDonald TM. The multiple propensity score for analysis of dose-response relationships in drug safety studies. Pharmacoepidemiol Drug Saf 2001;10(2):105-11. 19. Chatterjee S, Chen H, Johnson ML, Aparasu RR. Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity score-adjusted retrospective cohort study. Drugs Aging 2012;29(10):807-17. 20. Rowan CG, Brunelli SM, Munson J, et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2012;21(5):494-506. 21. Chitnis AS, Aparasu RR, Chen H, Johnson ML. Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: a multiple-propensity analysis. Res Social Adm Pharm 2012;8(2):145-56. 22. Huang IC, Frangakis C, Dominici F, Diette GB, Wu AW. Application of a propensity score approach for risk adjustment in profiling multiple physician groups on asthma care. Health Serv Res 2005;40(1):253-78. 23. Robst J, Armstrong M, Dollard N, Rohrer L. Arrests among youth after out-of-home mental health treatment: comparisons across community and residential treatment settings. Criminal behaviour and mental health : CBMH 2013;23(3):162-76. 24. Bhattacharya S, Abebe K, Simon M, Saba S, Adelstein E. Role of cardiac resynchronization in end-stage heart failure patients requiring inotrope therapy. J Card Fail 2010;16(12):931-7. 25. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002;62(1):13-59. 26. Frei CR, Labreche MJ, Attridge RT. Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use. Drugs 2011;71(6):757-70. 27. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007;41(11):1859-66. 28. Bertino J, Jr., Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000;22(7):798-817; discussion 797. 29. Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther 2010;88(2):214-22. 30. Lawrence KR, Adra M, Keir C. Hypoglycemia-induced anoxic brain injury possibly associated with levofloxacin. J Infect 2006;52(6):e177-80. 31. Singh M, Jacob JJ, Kapoor R, Abraham J. Fatal hypoglycemia with levofloxacin use in an elderly patient in the post-operative period. Langenbecks Arch Surg 2008;393(2):235-8. 32. Vallurupalli S, Huesmann G, Gregory J, Jakoby MGt. Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia. Diabet Med 2008;25(7):856-9. 33. Frothingham R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin Infect Dis 2005;41(9):1269-76. 34. LaPlante KL, Mersfelder TL, Ward KE, Quilliam BJ. Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. Pharmacotherapy 2008;28(1):82-9. 35. Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005;25(10):1303-9. 36. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354(13):1352-61. 37. Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004;24(12):1807-12. 38. Gibert AE, Porta FS. Hypoglycemia and levofloxacin: a case report. Clin Infect Dis 2008;46(7):1126-7. 39. Singh N, Jacob JJ. Levofloxacin and hypoglycemia. Clin Infect Dis 2008;46(7):1127. 40. Garber SM, Pound MW, Miller SM. Hypoglycemia associated with the use of levofloxacin. Am J Health Syst Pharm 2009;66(11):1014-9. 41. Kelesidis T, Canseco E. Levofloxacin-induced Hypoglycemia: A Rare but Life-threatening Side Effect of a Widely Used Antibiotic. Am J Med 2009;122(3):e3-e4. 42. Aspinall SL, Good CB, Jiang R, McCarren M, Dong D, Cunningham FE. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis 2009;49(3):402-8. 43. Lin G, Hays DP, Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J Toxicol Clin Toxicol 2004;42(3):295-7. 44. Kapoor R, Blum D, Batra A, et al. Life-threatening hypoglycemia with moxifloxacin in a dialysis patient. J Clin Pharmacol 2011. 45. Dear Customer Letter. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM089431.pdf. Accessed 4 Nov 2012. 46. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67(14):2077-99. 47. Smith KM, Lomaestro BM. What Role do Fluoroquinolone Antimicrobial Agents Play in Cardiac Dysfunction and Altered Glycemic Control? J Pharm Pract 2003;16(5):349-60. 48. Saraya A, Yokokura M, Gonoi T, Seino S. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004;497(1):111-7. 49. Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 2005;25(10):1296-302. 50. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007;29(4):374-9. 51. Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis 2012;55(11):1457-65. 52. Svanstrom H, Pasternak B, Hviid A. Use of Azithromycin and Death from Cardiovascular Causes. New Engl J Med 2013;368(18):1704-12. 53. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the Risk of Cardiovascular Death. New Engl J Med 2012;366(20):1881-90. 54. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 2005;104(3):157-63. 55. Ginde AA, Blanc PG, Lieberman RM, Camargo CA, Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord 2008;8:4. 56. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010;19(8):858-68. 57. Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003;51 Suppl 1:21-7. 58. Lewis RJ, Mohr JF, 3rd. Dysglycaemias and fluoroquinolones. Drug Saf 2008;31(4):283-92. 59. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 1996;117(2):372-6. 60. Ghaly H, Kriete C, Sahin S, et al. The insulinotropic effect of fluoroquinolones. Biochem Pharmacol 2009;77(6):1040-52. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16761 | - |
dc.description.abstract | 研究背景與目的:
為偵測藥物罕見副作用風險,隨機臨床對照試驗有其限制,因此如何適切的應用次級資料庫及多組傾向性分數,同時控制為數眾多之干擾因子,且考量多組治療間之比較,實為重要的議題。研究文獻雖業已指出fluoroquinolone類藥物具引起嚴重甚至致命的血糖異常及心律不整的可能性,然而過去研究多受限於研究樣本數不足,結果未有一致性,亦無針對fluoroquinolone類藥物間不同藥品進行相對風險比較的研究。 因此,本研究以台灣的全民健康保險大型資料庫,利用多組傾向性分數分析fluoroquinolone與嚴重心室心律不整及血糖不良反應之風險。 研究材料與方法: 本研究資料來源為全民健康保險資料庫及死亡登記檔的世代研究,選取研究期間內於門診接受口服研究抗生素的新使用者做為研究對象。以接受macrolides治療之病患做為血糖不良反應之參考對照組;接受amoxicillin/clavulanic acid治療之病患做為心室心律不整及心血管死亡反應之參考對照組;另選取第二代cephalosporins做為負控制組。 利用多組傾向性分數,以多變量邏輯式迴歸模型進行校正,而得各組抗生素對研究事件之粗勝算比和校正勝算比(aOR)及其 95% 信賴區間(confidence interval, CI)。再根據基本特性與重要共病進行分層分析,並以不同追蹤區間進行敏感度分析,分別以7天及14天之不同追蹤區間進行額外分析。 研究結果: 在心室心律不整研究中,以多組傾向性分數校正後之結果顯示,與amoxicillin-clavulanate類藥物相較,moxifloxacin及azithromycin顯著增加嚴重心室心律不整(aORs (95% CI), 分別為2.62 (1.78-3.86);2.88(2.05-4.04))及心血管死亡之風險(2.23 (1.60-3.11);1.98(1.43-2.75)),clarithromycin及ciprofloxacin組則並無觀察到有顯著風險增加。 同類藥物間之相互比較分析顯示,azithromycin對嚴重心室心律不整及心血管死亡之風險皆顯著高於clarithromycin,而moxifloxacin及levofloxacin亦顯著高於ciprofloxacin。在敏感性分析部分,分析結果顯示不論心室心律不整或心血管死亡,azithromycin、moxifloxacin及levofloxacin皆為於服藥後7天內風險最高,風險皆隨追蹤時間增加而遞減。 於樣本數影響力之模擬校正分析,研究結果顯示,在事件數較多時,分析結果較為穩健,故多組傾向性分數校正、pairwise配對及減少樣本數之抽樣校正分析結果和誤差皆相近。然而於發生率小於萬分之一之罕見事件時, pairwise配對及抽樣校正分析會損失大量對照參考組之事件數,導致統計檢定力下降,降低研究結果之精確(precision)程度,亦增加對風險估計之標準誤。 在嚴重血糖不良反應研究中,以多組傾向性分數校正後之hyperglycemia adjusted ORs (95% CI)分別為moxifloxacin 2.48 (1.50-4.12)、levofloxacin 1.75(1.12-2.73)、ciprofloxacin 1.87 (1.20-2.93);而hypoglycemia adjusted ORs (95% CI)分別為moxifloxacin 2.13 (1.44-3.14)、levofloxacin1.79 (1.33-2.42)、ciprofloxacin 1.45 (1.07-2.00),cephalosporins組則並無觀察到有顯著風險增加。Fluoroquinolones類藥物間的相互比較分析中,和ciprofloxacin相較,moxifloxacin顯著增加hypoglycemia之風險。 在同時合併使用胰島素或sulfonylurea之病患中,moxifloxacin皆顯著增加hypoglycemia之風險,而對接受glinides, metformin, 或thiazolidinediones治療之病患,所有fluoroquinolones皆顯著增加hyperglycemia的風險。在病患合併有慢性腎臟病,和同時接受sulfonylurea治療病患,levofloxacin皆顯著增加hypoglycemia的風險。在敏感性分析部分,結果顯示dysglycemia的效應並未隨觀察時間改變而有所不同 結論: 本研究結果顯示,適當的使用多組傾向性分數,可在同時考慮多組治療選擇下,犧牲最少統計檢定力,同時校正所有潛在的干擾因素,得到較精確之罕見事件風險估計。且於稀少事件數之下,依重要危險因子執行分層分析,以提供臨床治療選擇之重要依據。 經由多組傾向性分數校正分析,和amoxicillin-clavulanate相較,moxifloxacin及azithromycin顯著增加心室心律不整及心血管死亡風險。雖fluoroquinolones具群組效應,但在不同種類之fluoroquinolones存在程度上之差異,尤以moxifloxacin具最高的風險。 在糖尿病患中,和macrolides相比,fluoroquinolones顯著增加高血糖及低血糖之風險,且在不同種類之fluoroquinolones存在程度上之差異。在fluoroquinolones中,moxifloxacin有最高的風險造成低血糖,其次為levofloxacin及ciprofloxacin。合併有慢性腎臟病,以及正在接受insulin或sulfonylurea治療之糖尿病患,更為容易有血糖代謝不良反應。 | zh_TW |
dc.description.abstract | Background and objective:
Randomized control trial was limited to detect rare adverse drug effect. Therefore, how to appropriate using secondary database and multiple propensity score is an important issue. Several studies have indicated that a relationship exists between the use of fluoroquinolones and severe dysglycemia and arrhythmia. However, epidemiologic data regarding dysglycemia and arrhythmia risk with different fluoroquinolones were inconsistent. Therefore, to investigate the risk of severe ventricular arrhythmia and dysglycemia resulting from fluoroquinolones treatments, we performed a population-based study, using National Health Insurance database and multiple propensity score method. Materials and Methods: A population-based inception cohort study was conducted. Data was obtained from National Health Insurance claims data and the National Death Registry. We selected patients who had been prescribed amoxicillin/clavulanate as the reference group for severe ventricular arrhythmia risk assessment, and patients who had been prescribed macrolides as the reference group for severe dysglycemia risk assessment. Additionally, we selected patients who had been prescribed second generation cephalosporins as negative control group. We estimated multiple propensity scores for each of the studied drugs using multinomial logistic regression by considering covariates including comorbidities, health resource utilization, concomitant medication, and indication for antibiotics. The estimated multiple propensity scores were included in the multivariable logistic regression to estimate the crude and adjusted odds ratio (aOR) as well as the 95% confidence interval (CI) for the association between antibiotics and the risk of ventricular arrhythmia or dysglycemia. Stratified analysis was performed to evaluate potential effect modification. Furthermore, we performed sensitivity analysis for follow-up periods of 14 or 30 days to evaluate whether the effects were substantial. Results: The use of moxifloxacin and azithromycin showed a significant increase in the risk of both ventricular arrhythmia and cardiovascular death compared with amoxicillin-clavulanate treatments. The adjusted ORs (95% CI) for ventricular arrhythmia were 2.62 (1.78-3.86) for moxifloxacin and 2.88(2.05-4.04) for azithromycin. For cardiovascular death, the adjusted ORs (95% CI) for moxifloxacin and azithromycin was 2.23 (1.60-3.11), and 1.98(1.43-2.75) respectively. Neither clarithromycin nor ciprofloxacin were noted significant association with ventricular arrhythmia and cardiovascular death. In sample size simulation analysis, the results were more robust with sufficient number of events. However, pairwise match and sampling adjust analysis were lose enormous events of reference group, which can lead lower statistical power, less precision estimate. The adjusted odds ratios of levofloxacin, ciprofloxacin, and moxifloxacin compared with macrolides were 1.75 (1.12-2.73), 1.87 (1.20-2.93), 2.48 (1.50-4.12) for hyperglycemia and 1.79 (1.33-2.42), 1.46 (1.07-2.00), 2.13 (1.44-3.14) for hypoglycemia, respectively. No significant association was noted between cephalosporins and dysglycemia. Patients taking moxifloxacin faced a significantly higher risk of hypoglycemia than those receiving ciprofloxacin. When the results were stratified according to various anti-diabetic agents, the use of moxifloxacin increased the risk of hypoglycemia significantly among patients receiving concomitant insulin or sulfonylurea treatments. All types of fluoroquinolones significantly increased risk of a hyperglycemia event among patients treated with diet therapy and those receiving glinides, metformin, or thiazolidinediones. For levofloxacin, increased risk of hypoglycemia was evident among patients suffering from chronic kidney disease and those receiving concomitant sulfonylurea treatment. We obtained similar results in the sensitivity analysis using follow up periods of 7 and 14 days. Conclusion: Our study indicated that using multiple propensity score can adjust potential confounding factors and to analyze multiple treatment choice simultaneously with rare events. Moxifloxacin and azithromycin were significantly increase risk of severe ventricular arrhythmia and cardiovascular death. Diabetics using oral fluoroquinolones faced greater risk of severe dysglycemia. The risk of severe ventricular arrhythmia, cardiovascular death and hypoglycemia varied according to the type of fluoroquinolone administered, and was most commonly associated with moxifloxacin. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T23:45:27Z (GMT). No. of bitstreams: 1 ntu-103-D98846003-1.pdf: 2339194 bytes, checksum: e61dcaa2cc6e52e2eb1a3841e00aa796 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 摘要 2
Abstract 5 目錄 8 表目錄 10 圖目錄 11 第一章 前言 13 第二章 文獻回顧 14 第一節 觀察性藥物流行病學研究與傾向性分數之發展 14 1. 觀察性藥物流行病學研究於偵測藥物罕見副作用之優點及限制 14 2. 傾向性分數(propensity score)之發展、應用及限制 17 第二節 應用傾向性分數研究比較多組治療效果及副作用 19 1. 多組傾向性分數(multiple propensity score)之發展 19 2. 多組傾向性分數(multiple propensity score)於研究罕見事件之應用及限制 20 第三節 國內外利用多組傾向性分數分析之研究 22 第四節 Fluoroquinolones類藥物副作用之研究 25 1. 血糖不良反應 26 2. 心室心律不整 27 第五節 文獻回顧小結 28 第三章 研究目的及架構 30 第一節 研究目的 30 第二節 研究架構 31 第四章 研究材料與方法 34 第一節 Moxifloxacin, levofloxacin和ciprofloxacin相關嚴重心室心律不整和心血管死亡之風險比較分析,並探討多組傾向性分數不同應用方法結果之差異 34 第二節 Moxifloxacin, levofloxacin和ciprofloxacin相關之嚴重血糖不良反應風險 42 第五章 結果 50 第一節 Moxifloxacin, levofloxacin和ciprofloxacin相關之嚴重心室心律不整風險與心血管死亡風險 50 第二節 Moxifloxacin, levofloxacin和ciprofloxacin相關之嚴重血糖不良反應風險 79 第六章 討論與結論 91 第一節 討論 91 第二節 結論 100 第七章 參考文獻 101 | |
dc.language.iso | zh-TW | |
dc.title | 利用次級資料庫評估藥物罕見副作用風險之研究-fluoroquinolones之不良反應為例 | zh_TW |
dc.title | Using secondary database to evaluate rare drug risk–Adverse reaction of fluoroquinolones | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳建煒,邵文逸,李文宗,杜裕康,張家勳 | |
dc.subject.keyword | 多組傾向性分數校正分析,藥物罕見副作用風險評估,氟化奎諾酮抗生素,血糖不良反應,心室心律不整,藥物流行病學,世代研究,健保資料庫, | zh_TW |
dc.subject.keyword | multiple propensity score adjust,rare adverse drug reaction risk assessment,fluoroquinolones,dysglycemia,ventricular arrhythmia,pharmacoepidemiology,cohort study,National Health Insurance Research Database, | en |
dc.relation.page | 105 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2014-06-30 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 2.28 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。